Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05141136
Other study ID # 3-2021-0293
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 30, 2021
Est. completion date October 31, 2023

Study information

Verified date November 2021
Source Gangnam Severance Hospital
Contact Do Hyeong Kim
Phone 82-2-2019-4601
Email BREADFANS@yuhs.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to analyze the spread of local anesthetic using magnetic resonance imaging after thoracic 2 paravertebral block in patients with cervical radiculopathy.


Description:

1. Ultrasound guided thoracic 2 paravertebral block will be done using sagittal scan or transverse scan. 2. Clinical parameters will be monitored (temperature, perfusion index, assessment of sensory block and analgesic effect, vital sign, adverse events) after the nerve block. 3. Cervical MRI will be taken 1 hour after the nerve block. 4. Follow up 7 days and 28 days after the MRI at outpatient clinic (numeric rating scale, medication quantification scale)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 31, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Patients with unilateral radiating pain in the upper extremity whose pain persists for more than 3 months despite conservative treatment 2. Diagnosis: cervical degenerative disc disease, cervical foraminal stenosis, cervical stenosis with/without myelopathy 3. Numeric rating score = 4 4. 19 years or older Exclusion Criteria: 1. Cervical or upper thoracic spine surgical history 2. If the body mass index is 35 kg/m2 or more 3. If you have an allergy or hypersensitivity reaction to a local anesthetic 4. coagulation disorders 5. Local infection at the injection site 6. claustrophobia 7. If you have a metal insert such as a pacemaker 8. pregnancy 9. Patients who are unable to communicate and have cognitive impairment 10. If a person who cannot read the consent form is included among the subjects (e.g., illiterate, foreigners, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ultrasound probe sagittal group
Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
Ultrasound probe transverse group
Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.

Locations

Country Name City State
Korea, Republic of Gangnam Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Gangnam Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Injectate spread on MRI imge Presence of injectate on each anatomic target (Paravertebral space, ventral/dorsal epidural space, intercostal nerve, contralateral space) 1 hour after thoracic 2 paravertebral block
Secondary numeric rating score A score of 0 indicates no pain and a score of 10 indicates maximum pain. Before nerve block, after 30 minutes, and thereafter, at the outpatient visit on the 7th day and the outpatient visit on the 28th day.
Secondary perfusion index After the subject rests in the supine position for about 10 minutes, pulse oximetry is placed on the index finger to record the baseline value. Perfusion index was measured using pulse oximetry (Root®, Masimo Corporation, Irvine, CA, USA). The perfusion index can be a useful indicator for judging the After the subject rests in the supine position for about 10 minutes, pulse oximetry is placed on the index finger to record the baseline value. Perfusion index was measured using pulse oximetry (Root®, Masimo Corporation, Irvine, CA, ) Before nerve block, after 30 minutes
Secondary skin temperature Place a touch thermometer (IntelliVue MP70 patient monitor, Philips Healthcare, Best, Netherlands) on the palm of your hand and measure. Calculate the amount of change from the baseline. Record the difference with the contralateral hand. Before nerve block, after 30 minutes
Secondary pinprick and cold test Pinprick sensation was performed using a 22 gauge short bevel needle. Comparison with the contralateral dermatome. Sensation is rated as 0 (no sensation), 1 (decreased sensation), and 2 (normal). A sensory block is considered successful if the patient reports 0 or 1. Cold sensation is measured in the same way using an ice cube. If there is no difference in the sensation of the treated dermatome compared to the contralateral dermatome. Before nerve block, after 30 minutes
Secondary Blood pressure in mmHg Record blood pressure , and calculate the change from baseline. Before nerve block, after 30 minutes
Secondary Pulse rate in /min Record pulse, and calculate the change from baseline. Before nerve block, after 30 minutes
Secondary Presence of adverse events Horner syndrome, hoarseness, dyspnea, ptosis, dysphagia Before nerve block, after 30 minutes
Secondary medication quantification scale The Medication Quantification Scale (MQS) is an instrument with potential clinical and research applications for quantifying medication regimen use in chronic pain populations. Before nerve block, and thereafter, at the outpatient visit on the 7th day and the outpatient visit on the 28th day
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04381663 - CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes
Not yet recruiting NCT06092138 - Edge Computing Platform for Spine Health Risk Management Based on IoT Technology N/A
Completed NCT04039581 - KT® in Patients With Cervical Spine Surgery N/A
Completed NCT04774458 - Prospective Observation of the Fluoroscopy-guided Cervical Epidural Approach Using the Contralateral Oblique View N/A
Completed NCT01052324 - The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation Phase 4
Recruiting NCT05786313 - Study of Individualized, Precise and Standardized Cervical Open-door Surgery for Cervical Spinal Stenosis N/A
Recruiting NCT05895968 - Researching the Useful of Barb Suture in Obese Patients Undergoing Posterior Cervical Surgery N/A
Recruiting NCT05767164 - Correlation Between Parameters and Prognosis of Cervical Single Open-door Surgery N/A